Strategic alliance will put the world's leading population genomics system on China's leading cloud infrastructure – to support the delivery of China's Precision Medicine Initiative
- Huawei cloud platform serves 50,000 customers across China with data centers in 15 cities
- WuXi NextCODE genomics technology powers the leading population genomics and large-scale precision medicine efforts in the UK, Qatar, US and China
SHENZHEN, China, SHANGHAI, CAMBRIDGE, Massachusetts and REYKJAVIK, Iceland, March 17, 2016 /PRNewswire/ -- Huawei, a leading global information and communications technology provider, and WuXi AppTec, the global open-access R&D platform, have announced the signing of a strategic framework agreement to support the China Precision Medicine Initiative (China PMI) through the creation of a state-of the-art precision medicine cloud platform. The agreement builds on Huawei's industry-leading capabilities and reach in cloud infrastructure, and the unrivalled genomics and precision medicine expertise of WuXi NextCODE, the global genomic information and precision medicine subsidiary of WuXi AppTec.
Cloud computing is the way genomic big data will be used to drive precision medicine innovation and deliver better healthcare in a cost-efficient manner. WuXi AppTec and Huawei will follow the guidance of the China Food and Drug Administration (CFDA) and work closely with third-party secure life-science cloud providers to develop the data standards and exchange framework required to deliver the China PMI.
"We are excited and honored to be working with Huawei as our key public cloud technology partner to support the China PMI," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "This partnership aims to deliver the benefits of genomic medicine to patients on an unprecedented scale, and together we have the world-leading technology to achieve that ambition."
"This partnership is a win-win-win – for our companies and for the patients that will benefit from the vision of the China PMI," said Hannes Smarason, COO of WuXi NextCODE. "Our technology underpins genome-driven medicine at Genomics England, the Qatar Genome Project, Boston Children's Hospital and Harvard Medical School, and in China at Fudan University. We are thrilled to be deploying it with Huawei across China, a key part of our strategy to advance a global standard for turning the genome into better health."
Huawei is a leading global information and communications technology (ICT) solutions provider. Our aim is to enrich life and improve efficiency through a better connected world, acting as a responsible corporate citizen, innovative enabler for the information society, and collaborative contributor to the industry. Driven by customer-centric innovation and open partnerships, Huawei has established an end-to-end ICT solutions portfolio that gives customers competitive advantages in telecom and enterprise networks, devices and cloud computing. Huawei's 170,000 employees worldwide are committed to creating maximum value for telecom operators, enterprises and consumers. Our innovative ICT solutions, products and services are used in more than 170 countries and regions, serving over one-third of the world's population. Founded in 1987, Huawei is a private company fully owned by its employees.
About WuXi AppTec
WuXi AppTec is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi AppTec provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi AppTec is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi AppTec's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.
About WuXi NextCODE
WuXi NextCODE is a genomic information company applying sequence data to deliver better health and precision medicine for people around the world. Our uniquely comprehensive open-access capabilities include CLIA- and CAP-certified sequencing; a novel database architecture that mines and manages more genomes than any other; the world's leading genome interpretation and discovery system, available installed or in the cloud; a pioneering internet of DNA that enables users to query and collaborate using massive genomic datasets online with unrivalled resolution and efficiency; the know-how to apply genomics to optimize drug development; and a growing range of tests and scans to improve rare disease diagnosis, targeted cancer treatment, and wellness. With offices in Shanghai, Cambridge, Massachusetts and Reykjavik, we serve companies and health systems, clinicians and researchers, and people and populations worldwide. WuXi NextCODE is a subsidiary of WuXi AppTec.
SOURCE WuXi NextCODE